Across 185,237 statin initiators without prior cardiovascular disease, heart failure, or kidney disease in Hong Kong, New Zealand, and the UK, only 40% still had LDL cholesterol at or above 2.6 mmol/L two years in. Reaching 1.8-2.5 mmol/L carried a 20% lower hazard of major adverse cardiovascular events (HR 0.80, 0.77-0.83) versus staying above 2.6; 1.4-1.7 mmol/L gave HR 0.79. Non-HDL results matched. Risk fell roughly log-linearly with achieved LDL in two of three regions, and very low LDL showed no clear link to all-cause mortality.
The practical message is that statin prescription is only half the job: the number reached on treatment predicts outcomes, which supports follow-up lipid testing and dose adjustment instead of fire-and-forget prescribing. The log-linear pattern echoes Cholesterol Treatment Trialists' meta-analyses of randomized trials, and the reassuring mortality result at very low LDL adds to safety data. Caution is warranted, though. This is observational, and the authors acknowledge confounding by indication, since higher-risk patients often receive more intensive treatment. Those who reach lower LDL may also be more adherent and healthier overall (the healthy-adherer effect). The sub-1.4 group held only 3.8% of patients, so its estimate (HR 0.82, 0.60-1.12) is imprecise, and New Zealand's data were inconsistent at low concentrations. Treat this as confirmatory evidence that reinforces guideline targets in primary prevention rather than proof that lower is always better. Anyone on a statin should ask their clinician whether their on-treatment LDL has been rechecked.